Exciva Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$69.8M
- Investors
-
10
Exciva General Information
Description
Developer of an antitussive medication designed to address both the neurological and psychological aspects of behavioral and psychological symptoms. The company specializes in developing disease-modifying therapies, cures, prophylactics, supplements, formulations, and methods for making and using such compositions, enabling the healthcare industry to access its program for rescuing and repurposing approved drugs for new indications and uses.
Contact Information
Website
www.exciva.comCorporate Office
- Hauptstraße 25
- 69117 Heidelberg
- Germany
Corporate Office
- Hauptstraße 25
- 69117 Heidelberg
- Germany
Exciva Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 20-Jan-2026 | $69.8M | Completed | Clinical Trials - Phase 2 | ||
| 2. Later Stage VC (Series A) | 26-Oct-2021 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC | 01-Jan-2019 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Exciva Patents
Exciva Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026156036-A1 | Compositions and methods for enhancing deramciclane therapeutic concentration | Pending | 14-Jan-2025 | ||
| WO-2026156077-A2 | Compositions and methods for modulating plasma levels of brain-derived neurotrophic factor | Pending | 14-Jan-2025 | ||
| WO-2026156077-A3 | Compositions and methods for modulating plasma levels of brain-derived neurotrophic factor | Pending | 14-Jan-2025 | ||
| CA-3062452-A1 | Compositions, combinations, and methods thereof for treatment of neurological disorders | Active | 04-May-2017 | ||
| CA-3062452-C | Compositions, combinations, and methods thereof for treatment of neurological disorders | Active | 04-May-2017 | A61P25/00 |
Exciva Signals
Exciva Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CARMA FUND Management | Venture Capital | Minority | ||
| Dolby Family Ventures | Venture Capital | Minority | ||
| EQT Life Sciences | Venture Capital | Minority | ||
| Fountain Healthcare Partners | Venture Capital | Minority | ||
| Gimv | PE/Buyout | Minority |
Exciva FAQs
-
When was Exciva founded?
Exciva was founded in 2015.
-
Where is Exciva headquartered?
Exciva is headquartered in Heidelberg, Germany.
-
What is the size of Exciva?
Exciva has 5 total employees.
-
What industry is Exciva in?
Exciva’s primary industry is Drug Discovery.
-
Is Exciva a private or public company?
Exciva is a Private company.
-
What is Exciva’s current revenue?
The current revenue for Exciva is .
-
How much funding has Exciva raised over time?
Exciva has raised $80.3M.
-
Who are Exciva’s investors?
CARMA FUND Management, Dolby Family Ventures, EQT Life Sciences, Fountain Healthcare Partners, and Gimv are 5 of 10 investors who have invested in Exciva.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process